US 2006/0188440 A1Published application

Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer

AssigneeFox Chase Cancer Center

InventorsGregory Adams, Heidi Simmons, Qing-an Yuan, Wayne Marasco, Smita Mehta

Life of this patent

Estimating the term…

Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided.

Dependent claims

An isolated antibody having binding affinity for Mullerian Inhibiting Substance Type II Receptor (MISIIR).

Dependencies are inferred from the claim text.

C07K 16/2869
Against receptors, cell surface antigens or cell surface determinants: against hormone receptors
A61K 51/103
Against receptors, cell-surface antigens or cell-surface determinants: against receptors for growth factors or receptors for growth regulators
A61P 35/00
Antineoplastic agents
C07K 16/2863
Against receptors, cell surface antigens or cell surface determinants: against receptors for growth factors, growth regulators

From the US filing history. Foreign family members aren’t listed.

Loading patent…